Case Remain for Bal...
Health Care: Health Services
Response Genetics Inc. (RGDX: NASDAQ)
$1.38 -0.13 | -8.54%
05/21/13 - 12:31 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 9.04M | 1.70M | 4.12M | 7.06M |
| Receivables | 5.37M | 4.05M | 4.73M | 1.98M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 14.99M | 6.74M | 9.80M | 9.46M |
| Property, Plant & Equipment, Gross | 4.28M | 3.95M | 3.43M | 3.43M |
| Accumulated Depreciation & Depletion | 3.26M | 2.88M | 2.62M | 2.18M |
| Property, Plant & Equipment, Net | 1.02M | 1.07M | 805.82K | 1.25M |
| Intangibles | 575.41K | 44.42K | 0.00 | 0.00 |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 79.66K |
| Total Non-Current Assets | 1.60M | 1.11M | 805.82K | 1.33M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 16.59M | 7.85M | 10.60M | 10.79M |
| Accounts Payable | 1.19M | 1.49M | 1.25M | 729.10K |
| Short Term Debt | 1.16M | 1.15M | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 5.27M | 5.89M | 5.92M | 4.75M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 11.78M | 7.85M | 7.95M | 5.39M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 11.86M | 8.10M | 7.95M | 5.39M |
| Total Liabilities | 17.13M | 13.99M | 13.88M | 10.14M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -542.21K | -6.14M | -3.28M | 649.22K |
| Common Par | 232.41K | 134.33K | 122.94K | 152.97K |
| Additional Paid In Capital | 56.77M | 43.51M | 40.61M | 39.86M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -57.28M | -49.52M | -43.82M | -39.15M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -264.00K | -267.18K | -193.96K | -215.95K |
| Total Capitalization | -542.21K | -6.14M | -3.28M | 649.22K |
| Total Equity | -542.21K | -6.14M | -3.28M | 649.22K |
| Total Liabilities & Stock Equity | 16.59M | 7.85M | 10.60M | 10.79M |
| Total Common Shares Outstanding | 32.80M | 19.54M | 18.36M | 15.30M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 26.74M | 19.12M | 17.79M | 13.28M |
| Diluted Weighted Shares Outstanding | 26.74M | 19.12M | 17.79M | 13.28M |
| Number of Employees | 90 | 100 | 87 | 50 |
| Number of Part-Time Employees | 9 | 5 | 8 | 6 |
Portfolios with RGDX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- Userjaysan Portfolio 1
- Usercurry Portfolio 1
- Usercharlesl950 Portfolio 1
- UserWACKJDDUDE Portfolio 1
Latest RGDX Headlines from TheStreet
- Response Genetics, Inc. Announces Fourth Quarter And Year-End 2012 Financial Results 03.21.13 | 07:03 am
- Response Genetics To Present At The 25th Annual ROTH Conference 03.12.13 | 07:03 am
- Response Genetics, Inc. To Release Fourth Quarter And Year-End 2012 Financial Results And Host Conference Call On March 21, 2013 03.07.13 | 07:03 am
- 5 Under-$10 Stocks Setting Up to Trade Higher 11.30.12 | 12:11 pm
- 5 Stocks With Big Insider Buying 09.19.12 | 12:09 pm
- Insiders Trading ODP RGDX EGL BRKR 09.18.12 | 01:09 pm
- Maguire Properties, Compugen: Midday Volume Plays 05.11.10 | 11:05 am
- Director Sells $7.4M Worth of Copart 07.01.09 | 10:07 am
Press Releases for RGDX
- Response Genetics, Inc. To Offer Enhanced ALK Testing Program For Metastatic Lung Cancer Patients - Business Wire 06.28.12 | 08:06 am
- Response Genetics Announces Presentation Of Lung Cancer Study Results At 2012 American Society Of Clinical Oncology Annual Meeting - Business Wire 05.30.12 | 08:05 am
- Response Genetics, Inc. Announces First Quarter Financial Results - Business Wire 05.10.12 | 08:05 am
- Response Genetics, Inc. To Release First Quarter Financial Results And Host Conference Call On May 10, 2012 - Business Wire 05.04.12 | 08:05 am
- Response Genetics, Inc. Announces Year-End And Fourth Quarter Financial Results - Business Wire 03.27.12 | 08:03 am
- Response Genetics, Inc. Announces Appointment Of Stephanie Astrow, Ph.D., As Vice President, Research And Development - Business Wire 03.26.12 | 08:03 am
- Response Genetics, Inc. To Release Fourth Quarter And Full-Year 2011 Financial Results And Host Conference Call On March 27, 2012 - Business Wire 03.21.12 | 08:03 am
- Response Genetics Regains NASDAQ Compliance - Business Wire 02.21.12 | 07:02 am
- Response Genetics To Present At The 22nd Annual UBS Global Healthcare Services Conference - Business Wire 02.06.12 | 07:02 am
- Response Genetics Raises More Than $7.8 Million In Financing - Business Wire 02.02.12 | 07:02 am
Partner Headlines for RGDX
- Benzinga's Small Cap Movers for Friday November 30, 2012 - Benzinga 12.02.12 | 11:12 am
- Glaxo Increases Stake in RGDX - Analyst Blog - NASDAQ 09.18.12 | 09:09 pm
- Response Genetics: This Train Is About To Leave The Station - Seeking Alpha 02.16.12 | 09:02 am
- Response Genetics Stock Soars 31% On $7.8M Offering News - Seeking Alpha 02.03.12 | 08:02 am
- Biomarker Diagnostics Drive Personalized Medicine but Path to Market Still Rife With Hurdles - Seeking Alpha 07.07.10 | 07:07 am
- Three Promising Small-Cap Cancer Plays - Seeking Alpha 05.17.10 | 08:05 am
- Response Genetics: An Earnings Primer - Seeking Alpha 05.12.10 | 06:05 am
- UPDATE 1-Response Genetics inks deal with Glaxo, shares soar - Reuters 05.11.10 | 10:05 am
